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To investigate the molecular mechanisms underlying altered T cell response in renal cell carcinoma (RCC) patients, we compared
autologous and allogeneic CD8+ T cell responses against RCC line from RCC patients and their HLA-matched donors, using
mixed lymphocyte/tumor cell cultures (MLTCs). In addition, we analyzed the expression of molecules associated with cell cycle
regulation. Autologous MLTC responder CD8+ T cells showed cytotoxic activity against RCC cell lines; however the analysis of
the distribution of CD8+ T-cell subsets revealed that allogenic counterparts mediate superior antitumor eﬃcacy. In RCC patients,
a decreased proliferative response to tumor, associated with defects in JAK3/STAT5/6 expression that led to increased p27KIP1
expression and alterations in the cell cycle, was observed. These data deﬁne a molecular pathway involved in cell cycle regulation
that is associated with the dysfunction of tumor-speciﬁc CD8+ eﬀector cells. If validated, this may deﬁne a therapeutic target in
the setting of patients with RCC.
1.Introduction
Cancer is associated with immune deﬁciency but the biolog-
ical mechanisms underlying immune failure remain poorly-
deﬁned.T cellsarekey elementsin eﬀectivecancerimmunity
in RCC, a disease that has proven refractory to conventional
treatment modalities, such as chemotherapy and radiother-
apy [1]. On the contrary, RCC patients have been reported to
beresponsivetoimmunotherapeuticapproachesestablishing
the concept that RCC is an immunogenic tumor [2, 3].
GiventheperceivedimportanceofCD8+ Tcellsinmediating
antitumor immunity, and that Th1-skewed CD4+ Th cells
are required to support durable CD8+ T-cell immunity [4,
5], it becomes particularly important to understand how
dysfunctional or partially functional CD8+ T cells arise
and what molecular mechanisms underlie their activation
in patients with cancer. There is considerable interest in
gaining a better understanding of the composition of the
antitumor CD8+ T cell population, with regard to its various
functional subsets. Sallusto et al. [6] used CCR7 expression
status to deﬁne T cell memory subsets. Central memory
CD8+ Tc e l l s( T CM) express CCR7, a chemokine receptor
required for traﬃcking to secondary lymphoid organs.
In contrast, this marker is signiﬁcantly downregulated on
eﬀector memory CD8+ Tc e l l s( T EM). TCM have been shown
to mediate superior anti-tumor activity compared with TEM
[7, 8]. There is a third T cell memory subset, terminally
diﬀerentiatedCD8+ TEM cells(TEMRA),thatexpressCD45RA
but lack CCR7 expression. Notably, TCM have a higher
proliferative potential and greater resistance to apoptosis,
whereas TEM/TEMRA have a skewed TCR repertoire and are
characterized by a “senescent” replication history [9, 10].
Furthermore, the results of gene expression analyses have
revealed that TCM are characterized by high basal and2 Journal of Biomedicine and Biotechnology
cytokine-induced STAT5/6 phosphorylation, reﬂecting their
capacity for enhanced self-renewal versus eﬀector memory
cells, in particular, TEMRA [11].
The JAK3/STAT5/6 pathway is a crucial signal transduc-
tion component for many growth factor receptors and it has
beenshowntobenecessaryforthedownregulationofseveral
genes that inhibit the cell cycle. This pathway regulates
the expression of cyclin-dependent kinase (Cdk) inhibitors
p27,thehyperphosphorylationoftheretinoblastomaprotein
(Rb)geneproduct,andthereleaseofactiveE2FinTcelllines
[12]. In vivo studies have provided evidence of the role of
p27KIP1, a cell cycle inhibitory protein, in T cell proliferation
[13, 14]. High p27KIP1 levels were correlated with a decreased
proliferative response to IL-4 and IL-12 in STAT6 deﬁcient
T cells [15, 16]. Therefore, the characterization of cell cycle
regulatory proteins and the delineation of aberrations in
CD8+ T cell function are important to understand in the
context of tumor development and progression.
Inhibition of T-cell proliferation is an important aspect
of immunosuppression as observed in cancer patients, and
it represents a mechanism adopted by tumors to evade
immune rejection [17]. Various studies have led to the iden-
tiﬁcation of a pathway controlling the progression of cells
from quiescence, through G1, and into S phase involving the
activationofG1cyclin-dependentkinases(cdk),inactivation
of Rb and related proteins [18]. The transcription factors of
the E2F family and Id (inhibitor of DNA binding) protein
family play a central role in the regulation of cell growth
[19].Inparticular,E2F4andId2 areessentialforRbfunction
[20] and are involved in independent functions that are
orchestrated in order to allow for cell cycle progression. Id2
and E2F4 may compete for Rb binding; hence, Id2 may
function via the release of restraining pocket proteins on E2F
transcription. Deregulation of E2Fs transcriptional control
contributes to oncogenic transformation in vitro and the
development of metastasis in vivo [21].
In this paper, we have investigated RCC-speciﬁc CD8+
T cell response in RCC patients and HLA-matched normal
donors that were generated in mixed lymphocyte/tumor
cell cultures (MLTCs) in order to deﬁne molecular path-
ways associated with immune deviation in CD8+ Tc e l l
compartment in RCC patients. However, the generation of
autologous RCC-reactive T cells requires the availability of
established RCC cell lines, that can only be obtained from
a minority of patients. Thus, we established tumor cell
lines from the primary RCC tissue of patients undergoing
nephrectomy. In such patients as well as HLA-matched
normal donors, we studied the phenotypic and functional
proﬁle of autologous and allogeneic RCC-speciﬁc CD8+
T cells. In particular, we focused on the integrity of the
JAK3/STAT5/6 signaling pathway and its relationship with
cell cycle regulatory proteins, such as E2F4 and Id2, in order
to better understand relevant mechanisms of dysfunction
associated with CD8+ T cells isolated from RCC patients.
T cells from RCC patients displayed decreased proliferative
responses to tumor antigens, which was linked to defects
in JAK3/STAT5/6 expression (and to increased p27KIP1
expression and altered cell cycle progression/proliferation).
Interestingly, we observed a signiﬁcant correlation between
RCC CD8+ T subset phenotypes and such signaling defects,
providing a surrogate index for clinical immune deviation
that might be employed in the monitoring of patient
response to immunotherapy.
2.MaterialandMethods
2.1. Cell Lines. Cell lines were generated from primary kid-
ney tissue explants of 13 patients with RCC. Freshly isolated
tumor tissue was minced, then digested using an enzymatic
cocktail as described previously [22]. Corresponding normal
renal cell lines (proximal tubular epithelial cells, PTEC)
were established from tumor-distal normal kidney tissue and
cultured in complete medium. Epstein-Barr virus- (EBV-)
transformed lymphoblastoid cell lines (LCL) were also gen-
erated from patient RCC1 PBMC (RCC1-LCL) and healthy
donor-2 (donor-2-LCL) using the B95.8 (type 1) virus
isolate. Allogeneic phytohemagglutinin- (PHA-) activated
T cell blasts (PHA-B) from donor-2 and donor-3 (donor-
2-PHA-B, donor-3-PHA-B) were prepared by stimulating
PBMC in media containing 2μg/mL PHA (Sigma) and IL-
2 (250 IU/mL, Proleukin, Chiron, Emeryville, CA).
2.2. Isolation of PBMC and HLA Typing. Peripheral blood
mononuclear cells (PBMCs) were obtained from RCC
patients and HLA-matched healthy donors after written
consent, under an IRB-approved protocol. All patients had
histological conﬁrmed RCC, clear cell subtype, and had not
received preoperative therapy. To determine the HLA-class I
genotype of donor PBMCs and RCC lines, individual alleles
wereampliﬁedfromgenomicDNAwithA/B/Callele-speciﬁc
primers and were then completely sequenced (Table 1,D r .B .
Favoino, Laboratory of typing tissue).
PBMCs were isolated at the interface of Ficoll-Hypaque
density gradients centrifugation (Sigma Chemical Co., St
Louis, MO), per the manufacturer’s instructions, washed
twice in PBS 3 (Invitrogen-Life Technologies, Italy) and used
in mixed lymphocyte/tumor cell cultures as described below.
2.3. Isolation of CD8+ T-Eﬀector Cells. CD8+ Tc e l l sw e r e
isolated from the PBMC of autologous and allogeneic
normal, healthy donors by positive selection using speciﬁc
MACS magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany) on MiniMACS columns, per the manufacturer’s
protocol and subsequently assessed for their functional and
phenotypic proﬁles.
2.4. Mixed Lymphocyte/Tumor Cell Cultures (MLTCs).
PBMCs from RCC patients or HLA-matched healthy
donors were cocultured in 24-well plates (Costar, Corn-
ing, USA) at 106 cells/well with irradiated RCC stimulator
cells (105 cells/well) in 2 mL of AIM-V medium (Life
Technologies, Invitrogen, Italy) supplemented with 10%
heat-inactivated pooled human serum (Sigma (medium
Mb)). Recombinant human IL-2 was added on day 3 at
a ﬁnal concentration of 250IU/mL (Proleukin, Chiron,
andEmeryville,CA).Responderlymphocytes(106 cells/well)
were restimulated weekly with 105 irradiated tumor cells inJournal of Biomedicine and Biotechnology 3
Table 1: HLA-class I genotyping of RCC patients and healthy donors.
HLA-A HLA-B HLA-Cw
RCC1 0301 2402 0702 0801 0702 0702
Donor 1a 0301 2402 0702 0801 0702 0702
Donor 1b 0301 2402 0702 0801 0702 0702
RCC2 0301 2402 1806 3506 0401 0702
Donor 2 0301 2402 1806 3506 0401 0702
RCC3 2402 3302 3506 6506 0401 0702
Donor 3 2402 3302 3506 6506 0401 0702
RCC4 0301 2402 1806 3506 0401 0702
Donor 4 0301 2402 1806 3506 0401 0702
RCC5 0201 28 3506 5104 0401 0702
Donor 5 0201 28 3506 5104 0401 0702
IL-2-containing medium Mb for 2 weeks before CD8+ T
cells isolation. CD8+ T cell isolation was performed using
immunomagneticCD8+ beads(MiltenyiBiotec,Milan,Italy)
and positively isolated T cells cultured for an additional 2
weeks. On day 35 of culture, CD8+ T cells responders were
used as eﬀector cells in functional and molecular analyses.
2.5. IFN-γ ELISPOT Assay. CD8+ T cell responders were
assessed for their ability to secrete IFN-γ in response
to speciﬁc stimulation using ELISPOT assays (Mabtech,
Mariemont, OH), as previously described [23]. Determi-
nations were performed in triplicate and spots were enu-
merated using an automatic plate reader (Zeiss-Kontron,
Jena, Germany). In some cases, the HLA-restriction of T
cell recognition was determined by addition of blocking
antibodies (ﬁnal concentration = 100μg/mL) to replicate
ELISPOT wells. Antibodies included; W6/32, an anti-HLA
class I, α-gap A3, an anti-HLA-A3, B1.23.2, an anti-HLA-
B and HLA-CA24, an anti-HLA-A24, L243, an anti-HLA
class II-DR. IgG2a isotype-matched control Abs were used
as negative controls.
2.6. 51Chromium-Release Assay. Responder CD8+ Tc e l l s
were evaluated for their ability to kill target cells including
patient-derived RCC cell lines, PHA-blast or EBV-cells and
K562 in standard 4h 51Cr-release assays [23].
2.7. Phenotypic Analysis. T cells were washed and resus-
pended in FACS buﬀer (phosphate-buﬀered saline pH
7.2, 0.2% bovine serum albumin, and 0.02% sodium
azide) containing 3% human serum and incubated with
ﬂuorochrome-conjugated mAbs for 15 minutes at 4◦C, then
washed with the same buﬀer before the performance of 6-
color ﬂow cytometry. For the surface staining of T cells,
ﬂuorescently labeled mAbs were used: PE-CD3, APC-CD8,
FITC-CD45RA, PerCP-CD28, (all BD-9Pharmingen), Pe-
Cy-7-CCR7 (R&D Systems), and APC-Cy-7-CD27. Flow
data were acquired using a FACSortTM (Becton Dickinson)
ﬂow cytometer and analyzed using WinMDI version 2.8
software.
2.8. Cell Cycle Analysis. T cells were ﬁxed in 70% ethanol
for 24 hours, prior to being treated with 50mg of RNase
A/mL at 37◦C for 30minutes After resuspension in 0.5mL
of propidium iodide solution (50pg/mL propidium iodide,
0.1% sodium citrate, and 0.1% Nonidet P-40) and a 30-
minutes incubation in the dark at 4◦C, the cellular DNA
content was analyzed by ﬂow cytometry using WinMDI
version 2.8 software.
2.8.1. Confocal Analysis. The expression of STAT5, STAT6,
p-27KIP1, E2F4, and Id2 in T cells was analyzed by confocal
ﬂuorescence microscopy using speciﬁc Abs (Santa Cruz
Biotechnology, DBA, Italy). CD8+ T cells were allowed
to adhere to poly-L-lysine-coated slides (Sigma-Aldrich,
Italy) for 1 hour on ice, followed by ﬁxation in 3.7%
paraformaldehyde. After washing three times with PBS
(pH 7.4), and being blocked with BSA 1% and PBS, cells
were stained with anti-pSTAT5 Ab, anti-pSTAT6 Ab, anti-
E2F4 Ab, anti-p27KIP1 Ab and anti-ID2 Ab. After washing,
T cells were than incubated with ﬂuorescently labeled
secondary Abs: Alexa Fluor FITC- and TRITC-conjugated
anti-Ig (Molecular Probes, Eugene, OR). Stained cells were
then washed four times with PBS, air-dried, and mounted
using Gel/Mount (Biomedia, Foster City, CA). Samples were
analyzed using a laser scanning Leica TCS SP2 confocal
microscope (Leica, Wetzlar, Germany) equipped with argon
krypton (488nm), green-neon (543nm), and helium-neon
(633nm) lasers. The expression levels of pSTAT5/6, p-27KIP1,
E2F4, and Id2 were measured in at least 15 high-power ﬁelds
(HPFs; 63×)/section by two independent observers blinded
to the origin of the slides. The ﬁnal count was the mean of
the two measures ± standard deviation (SD). In no case the
interobserver variability exceeds 20%.
2.8.2. Statistical Analysis. Data are reported as mean ±
standard deviation (SD) and analyzed for diﬀerences using
an unpaired Student’s t-test. Statview software package (SAS
Institute Inc. Cary, NC, USA; 5, 0 version) was used for
all analyses. P values <. 05 were considered statistically
signiﬁcant.4 Journal of Biomedicine and Biotechnology
3. Results andDiscussion
3.1.SelectiveExpansionofAutologousandAllogenicAntitumor
CD8+ TC e l l sb yM L T C .In our initial set of experiments,
we attempted to establish primary RCC lines from 13
patients who underwent radical or partial nephrectomy
for unilateral renal cell carcinoma. However, given limited
quantities of available tissue, we were only able to develop 5
RCClineswhichexhibitedwiththeappropriatemorphology,
histopathology, and immunohistochemical characteristics of
(clear-cell) RCC. Autologous and HLA-matched allogeneic
PBMCs isolated from normal, healthy donors (Table 1)
were used as responder cells to these tumor cells in MLTC
established in the presence of high dose rhIL-2. After 3
weeks of culture, responder cells were harvested and MACS-
puriﬁed CD8+ T cells were restimulated in an identical
fashion (to the primary induction) for additional 2 weeks.
Onday35ofculture,CD8+ Tcellswereevaluatedforspeciﬁc
anti-RCC reactivity using IFN-γ ELISPOT assays and 51Cr-
release assays.
In a ﬁrst example of the results obtained, we examined
autologous and allogeneic CD8+ T cell responses against the
RCC1 cell line. Interestingly for this model, we employed
2 allogenic responders: donor 1a (a healthy sibling to
the patient) and donor 1b (a healthy unrelated donor).
As shown in Figure 1(a),o nd a y0( T 0 )C D 8 + Tc e l l s
isolated from RCC1 patient’s PBMC displayed an elevated
(HLA class I-restricted) reactivity against the autologous
RCC1 cell line versus unstimulated CD8+ T cells isolated
from either of the healthy donor controls (Figures 1(b)
and 1(c), resp.), which was statistically signiﬁcant (P<
.03). After MLTC, the generated patient’s CD8+ Tc e l l s
continued to recognize RCC1 tumor cells, but they failed to
react against autologous nonmalignant kidney cells (PTECs)
or autologous PHA blasts (Figure 2(a)). T cell reactivity
against the RCC1 line was MHC class-I restricted, with
mAbs directed against single HLA-A (i.e., HLA-A24) or
common HLA-B/-C determinants inhibiting speciﬁc T cell
recognition of tumor cells by 75.5% and 43.4%, respectively
(Figure 2(b)). An analysis of T cells generated from the
patient’s sibling (i.e., MLTC2) revealed that the responder
CD8+ T cells recognized the HLA-matched RCC cell line
to a statistically greater degree than observed from the
patient’s own CD8+ T cells (P<. 05), while responding
against the K562 LAK/NK target cell line to a moderate
level (Figure 2(c)). These CTL recognized the RCC1 cell line
in a predominantly class I-restricted manner based on the
ability of the anti-A24 and anti-HLA-B/C mAbs to inhibit
responses by 52.3% and 70.7%, respectively. Finally, in the
case of the HLA-matched, unrelated donor (i.e., MLTC3), we
observed the greatest capacity (versus MLTC1 and MLTC2)
of CD8+ T cells to respond to the RCC1 cell line (P<. 03;
Figure 2(d)). Anticlass I blocking studies identiﬁed HLA-
A24 (28% inhibition) and HLA-A3 (57.8% inhibition) as the
predominant HLA-restricting elements for MLTC3 T cells.
In all the three anti-RCC1 T cell systems studied, ELISPOT
assays showed that T lymphocytes speciﬁcally secreted IFN-
γand granzyme B, but not interleukin-5 (IL-5), supporting
dominant Type1 T cell responsiveness (data not shown).
CD8+/RCC1
Anti-class I
Anti-DR
∗
RCC1 patient
0 2 04 06 08 0 1 0 0
20000 IFN-γ spots/wells
(a)
CD8+/RCC1
Anti-class I
Anti-DR
Donor-1a
0 2 04 06 08 0 1 0 0
20000 IFN-γ spots/wells
(b)
CD8+/RCC1
Anti-class I
Anti-DR
Donor-1b
0 2 04 06 08 0 1 0 0
20000 IFN-γ spots/wells
(c)
Figure 1: IFN-γ Elispot Assay CD8+ T cells isolated at day 0.
RCC1 cell line as stimulator cells and CD8+ T cells isolated from
PBMC of RCC1-patient (a) and their allogeneic donor-1a (b) and
donor-1b (c) at day 0 were tested in 20h IFN-γ-Elispot Assay. HLA
restriction of anti-RCC reactivity was determined by adding mAbs
speciﬁc for total HLA-class I and HLA-DR. Results represent the
average (± SD) of triplicate wells and the presented data derive
from 1 representative experiment of 5 performed. A paired t-test
analysis was used to compare the frequencies of autologous versus
allogenic speciﬁc CD8+ T cells stimulated with RCC1 cell line,
after subtraction of HLA class I reactivity; P<. 03 was considered
statistically signiﬁcant (∗).
Analysis of cytotoxic CD8+ T cell responses using 51Cr-
release assays similarly indicated a hierarchy of MLTC3 (75%
lysis at an E/T ratio of 20 : 1) > MLTC2 (55% lysis) >
MLTC1 (40% lysis) T cell response against the RCC1 cell
line (Figures 3(a)–3(c)). MLTC1 and MLTC2 T cells also
mediated moderate cytolysis of K562 cells, but not RCC1-
LCL (Figures 3(a) and 3(b)), while MLTC3 T cells recognized
RCC1-LCLs(65%lysisatanE/Tratioof20 : 1)butnotK562
cells (Figure 3(c)).
3.2. Diﬀerential Turnover of the CD8+ Memory T Cell Subset
in RCC Patients after MLTC Stimulation. Given the per-
ceived importance of CD8+ T cells in mediating anti-tumorJournal of Biomedicine and Biotechnology 5
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Figure 2: IFN-γ ELISPOT analyses of RCC-speciﬁc CD8+ T cell responses after MLTC. RCC1 CD8+ T cells stimulated by MLTC were tested
for their reactivity against HLA-matched target cells such as autologous RCC, PTEC, and PHA-activated PBMC, (a). In panels (b), (c), and
(d), K562 cells served as targets. A paired t-test analysis was used to compare the frequencies of autologous responder-CD8+ Tc e l l sv e r s u s
allogenicresponder-CD8+ Tcellsgenerated fromthepatient’ssibling(
∗P <. 05)andunrelateddonor(§P <. 03),stimulatedwithRCC1line.
The HLA restriction of the anti-RCC T cell response was determined by addition of blocking mAbs speciﬁc for total HLA-class I, HLA-A24,
HLA-A3, or HLA-B/-C alleles. Results represent the average (± SD) of triplicate wells and the presented data derive from 1 representative
experiment of 5 performed.
immunity, we extended our characterization of autologous
and allogenic RCC-speciﬁc CD8+ T cells generated from
MLTC, using 6-color ﬂow cytometry, focusing on markers
of T cell activation, proliferation, and diﬀerentiation. In
a g r e e m e n tw i t hp r e v i o u ss t u d i e s[ 6, 10], four distinct
phenotypic subsets of responder CD8+ T cells could be
identiﬁed using CD45RA and CCR7 as markers. Whereas
naive T cells express both CD45RA and CCR7, memory T
cells were characterized by the down regulated expression
of CD45RA and could be additionally subdivided, based on
diﬀerential expression of CCR7, into eﬀector memory (TEM:
CD45RA
−, CCR7−) and central memory subsets (TCM:
CD45RA
−, CCR7+). Several recent reports have deﬁned
the CD45RA+/CCR7− T cell subset (TEMRA)a sterminally
diﬀerentiated eﬀector T cells which lack CD27 and/or CD28
expression and are able to migrate to inﬂamed tissues, where
they may exert vigorous ex vivo eﬀector functions, including
target cell lysis [24, 25].
CD8+ T cells were puriﬁed from PBMC isolated from 5
RCC patients as well as HLA-matched normal donors and
analyzed for their phenotypes on day 0 (T0) and after 5
w e e k so fM L T Cc u l t u r e(T 3 5 ;Table 2). Freshly isolated CD8+
T cells from RCC patients displayed a predominant memory
phenotype comprised of TEM and TEMRA, while similarly
isolated CD8+ T cells from healthy donors exhibited a
predominantly na¨ ıve (i.e., CD45+, CCR7+) phenotype, with
lower percentages of TEMRA cells and comparable levels of
TCM and TEM cells. As expected, after 35 days of MLTC, the
percentageofna¨ ıveTcells(versusT0)declinedinallsubjects,
and the percentage of TCM increased, most notably in the
normal donor MLTC (59% ± 4.6) versus the patient MLTC
(11 ± 2.8%).
When taken together, these data are in line with previous
reportsinwhichtumor-reactiveCD8+ TCM mediatesuperior
anti-tumor eﬃcacy when compared with TEM [7, 26]. In
contrast, MLTC stimulation induced higher frequencies of6 Journal of Biomedicine and Biotechnology
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Figure 3: Cytotoxicity assay of RCC1-speciﬁc CTL at day 35 of the MLTC. Speciﬁc lysis was determined in a 4-hour 51Cr-release assay using
CD8+ T cells collected from d35 MLTC established from patient RCC1 (a) or HLA-matched normal donors (the patient’s sibling (b) and
an unrelated individual (c). T cells were used at varying eﬀector-to-target (E:T) cell ratios against target cells including RCC1, K562, and
RCC1-LCL. Data are presented as percentages of speciﬁc lysis ± SD.
Table 2: Flow cytometry analysis of CD45RA/CCR7 expression on CD8+ T cells at day 0 and after 35 days of MLTC. Diﬀerential expression
of the CD45RA, CCR7 cell surface molecules was analyzed on CD8+ T cells at day 0 and after extended MLTC stimulation. CD8+Tc e l l sw e r e
separated into four subsets (TN, TCM,TEM,TEMRA)b a s e do nd i ﬀerential expression of the CD45RA and CCR7 markers. Results are the mean
(+/− SD) of values obtained from 5 RCC patients and their corresponding HLA-matched normal donors.
CD8+ Naive TCM TEM TEMRA
CD45RA+CCR7+ CD45RA
−CCR7+ CD45RA
−CCR7− CD45RA
+CCR7−
Day 0 Day 35 Day 0 Day 35 Day 0 Day 35 Day 0 Day 35
RCC patients 30.6 ± 4.0 4.4 ± 1.6 8.2 ± 2.3 11 ± 2.8 14 ± 3.8 52.6 ± 6.7 46 ± 5.3 30.6 ± 4.2
Healthy donors 49 ± 3.1 3.1 ± 1.6 10.8 ± 5.3 59 ± 4.6 20.2 ± 3.9 32.8 ± 7.2 17.4 ± 3.6 4.4 ± 1.8
P value .021 .139 .019 .008 .034 .003 .0017 .0006Journal of Biomedicine and Biotechnology 7
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Figure 4: Characterization of the TEMRA population in RCC patients. Based on CD28/CD27 expression, CD8+T cells were separated into
threedistinctpopulations:pE1(RA+CCR7−27+28+),pE2(RA+CCR7−27+28−),andE(RA+CCR7−27−28-).Resultsaredepictedforpatients
RCC2 but are representative of all 5 RCC patients evaluated.
CD8+ TEM (and predominantly TEMRA) from RCC patients
versus normal donors. Given this diﬀerence, we further
characterized the TEMRA subpopulation of CD8+ Tc e l l s
generated from RCC patients versus normal donors with
regard to comparative levels of expression of the CD27
and CD28 markers (Figure 4). In accordance with the
model proposed by Rufer et al. [10], we identiﬁed three
functionally distinct CD8+ TEMRA (RA+CCR7−) subsets in
RCC patients: pE1 (27+28+), and pE2 (27+28−), and E
(27−28−) that have been deﬁned “early”, “intermediate,” and
“late” phenotypes, respectively, based on a proposed linear
pathway of diﬀerentiation.
Our data suggest that activated CD8+ T cells isolated
from RCC patients were more likely to be in a state
of intermediate diﬀerentiation (pE2) when compared to
normal donor CD8+ T cells. Indeed, we noted a profound
increaseinTcellexpression ofCD27afterMLTCstimulation
(from (T0) 19% ± 3.8 to (T35) 62% ± 4.1). Given previous
reports that the level of CD27 expressed by CD8+ Tc e l l s
correlates inversely with the ability of these cells to mediate
cytotoxic functions [27], our results intimate that the
reduced cytotoxic activity observed for CD8+ Tl y m p h o c y t e s
in RCC patients may be due to their lack of terminal
(functional) diﬀerentiation.
3.3. Cell Cycle Dysfunction in Activated CD8+ TC e l l s
from RCC Patients. To further investigate the relationship
between cell cycling and T cell diﬀerentiation status, we
evaluated the expression pattern of cell cycle proteins
involved in the G1/S transition in CD8+ T cells isolated from
RCC patients vs. normal donors on day 35 of MLTC. It
has been well established that initiation of T lymphocytes-
mediated immune responses involves two cellular processes:
entry into the cell cycle (G0 → G1) for clonal proliferation
and coordinated changes in surface and secreted molecules
that mediate eﬀector functions, associated with the diﬀer-
entiation of T lymphocytes into an eﬀector or memory
subpopulations. As shown in Figure 5,a c t i v a t e dp a t i e n t
CD8+ T cells were mainly present in the G0/G1 phase (85.7
± 2.08 vs. 63.3 ± 5.5) and less in the S phase (1.41 ± 0.18
vs. 12 ± 4.5) when compared with CD8+ T cells generated
in normal donor MLTC. A statistically signiﬁcant negative
correlation was noted between phases G1 and S (r =− 0.95,
P<. 05) in the patients’ T cells, suggesting that in RCC
patients there was an arrest at this cell cycle transition point
(Figure 6).
3.4. Association between Cell Division and Tumor Responsive-
ness in Activated RCC CD8+ TC e l l s .To better understand8 Journal of Biomedicine and Biotechnology
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Figure 5: Cell cycle analysis of responder-CD8+ Tc e l l sa f t e rM L T C . Cellular DNA content was analyzed in three RCC patients and their
HLA-matched normal donors by ﬂow cytometry, with data analyzed on WinMDI version 2.8 software.
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Figure 6: Alterations in the cell cycle distribution of patient versus
norma donor anti-tumor CD8+ T cells. A statistically signiﬁcant,
negative correlation was observed between G1 and S percentages in
3 RCC patients.
the association between T cell cycling and anti-tumor tumor
responsiveness, we assessed day 0 and day 35 MLTC CD8+
T cells for their expression of p27KIP1 and STAT5/6, proteins
knowntoberequiredfornormalTcellproliferation[15,28].
IL2-mediated downregulation of p27KIP1 is crucial for the
normal progression of CD8+ T cells from the G1 phase to
the S phase of the cell cycle. Activation of the JAK3/STAT5/6
pathway is required for p27KIP1 downregulation, hyperphos-
phorylation of RB, and release of active E2F in T cells. When
we analyzed STAT5 expression (Figure 7(a)), we found that
IL-2-induced STAT5 phosphorylation was readily detectable
in normal T cells (64.5 ± 5.3 /HPF and 71 ± 6.1/HPF
resp.)butresultedmarkedlyreducedinRCCpatients(22.1 ±
3.3/HPF, P<. 001). Interestingly, as displayed in Figure 7(b),
we observed that STAT6 expression decreased in patients
(40.2 ± 4.6/HPF), but not normal donors (57.3 ± 6.8/HPF
and 60.8 ± 1.7/HPF resp., P<. 0032) MLTC CD8+ T
cells.
This suggests that, despite the presence of high doses of
rhIL-2, the inability of patient CD8+ T cells to proliferate in
MLTC likely results from defects in the JAK3/STAT5/6 sig-
naling pathway. To test this hypothesis, we evaluated p27KIP1
expression status in MLTC CD8+ T cells developed from
RCC patients vs. normal donors. We observed that T cell
expression of p27KIP1 was increased in T cells from patients
(17.5 ± 3.2/HPF) vs. normal, healthy donors (8 ± 1.55/HPF
and 10.2 ± 0.37/HPF, P = .0046 resp.) (Figure 7(b)).
ThesedatasuggestthattheintegrityoftheJAK3/STAT5/6
pathway is likely linked to T cell division and that activated T
cells that fail to divide upon appropriate stimulation present
with operational defects in this pathway.
In order to conﬁrm that G1/S regulatory defects were
present in MLTC CD8+ T cellsdeveloped fromRCC patients,
we next investigated these cells for expression of two key
factors in the control of the G1–S-phase transition, E2F4 and
Id2, which might confer a proliferative advantage to tumor
cells in vivo [21, 29]. As shown in Figure 8, E2F4 expression
was reduced in MLTC CD8+ T cells from patients (11.2 ±
3.2/HPF) vs. normal donors (14.71 ± 1.0.28/HPF and 16.6
± 2.8/HPF, P = .0018 resp.). We also found that CD8+ T
cells from patients expressed lower levels of Id2 vs. normal
donor T cells (28.7 ± 4.3/HPF vs. 56.9 ± 8.4/HPF and 34.8 ±
6.5/HPF, P = .037, resp.), conﬁrming an arrest in the G0 cell
cycle phase among patient T cells (Figure 9).Journal of Biomedicine and Biotechnology 9
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Figure 7: Altered expression of pSTAT5, pSTAT6, and p27KIP1 in RCC patient CD8+ T cells. (a) Distribution of pSTAT5 evaluated by
confocal microscopy on CD8+ T cells of RCC patients and their HLA-matched normal donors, using anti-STAT5 (green) antibodies. (b)
The distribution of p-p27KIP1 and pSTAT6 were evaluated by confocal microscopy on CD8+ T cells of RCC patients and their HLA-matched
normal donors, using anti-p-p27KIP1 (red) anti-STAT6 (green) antibodies. p27KIP1/STAT6 interaction results in a yellow staining in the
merge. Quantitative analysis of high-power ﬁelds (HPFs) in (a) and (b) was carried out by confocal microscopy software (Leica, TCS-SP2).
The results were expressed as mean values ± SD. A P-value <. 05 was considered statistically signiﬁcant. Data are from 1 of 5 experiments
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4. Conclusions
Theexperimentalapproachesusedinourstudyprovidevalu-
able tools to assist in the elucidation of cellular mechanisms
underlying the altered activation state of T cells in patients
with cancer. We used RCC as a model cancer to explore
this question, as it is well documented that patients with
active, disseminated disease are typically characterized by
“functionally inappropriate”, dysfunctional, or proapoptotic
immune cells that are impotent in mediating clinically
beneﬁcial outcomes in vivo [30, 31].
We conﬁrmed that it is possible to generate and expand
tumor-reactive CD8+ T cells in vitro from the peripheral
bloodofRCCpatientsaswellasnormaldonors[32].Normal
donor RCC-speciﬁc CD8+ T cells appeared to recognize
a diverse array of antigens and displayed superior anti-
tumor activity when compared with patient-derived CD8+ T
cells [23]. Normal donor CD8+ T cells developed in MLTC
cultures also demonstrated signiﬁcant reactivity against
K562 target cells (in contrast to patient MLTC-derived CD8+
T cells), supporting the conclusion that these allogenic
MLTC-CD8+ T cells were capable of mediating HLA class I-
restricted as well as HLA-unrestricted cytotoxicity.
A corollary analysis of the phenotypes of allogenic and
autologousMLTC-CD8+ Tcellspredicatedonarecentlypro-
posed pathway of T-cell lineage diﬀerentiation [6] revealed
that the majority of freshly isolated CD8+ Tc e l l sf r o m
RCC patients display a memory phenotype characterized
by very low frequencies of CD45RA
−, CCR7+TCM cells,
high frequencies of CD45RA
−, CCR7−TEM, and terminally
diﬀerentiated CD45RA+, CCR7−TEMRA. Interestingly, we
noted that after MLTC expansion, patient CD8+T cells are
mainly composed of antigen-experienced TEM and TEMRA
and are deﬁcient in TCM. In sharp contrast, MLTC-CD8+ T
cellsdevelopedfromnormaldonorscontainhighfrequencies
of TCM population and far lower percentages of both TEM
and TEMRA cells. These data are particularly important as
tumor-reactive CD8+ TCM have been previously suggested
to provide superior anti-tumor protection vs. TEM [7, 26].
Furthermore, it has been shown that TCM exhibit greater
expansion potential in concert with enhanced resistance to
apoptosis,whereasTEM/TEMRA have a skewed TCR repertoire
and proliferate poorly in response to cognate antigen [9].
Importantly, our study revealed that patients CD8+ TEMRA
expandedinMLTCaremorelikelytoexhibit anintermediate
state of diﬀerentiation (i.e., CD27+, CD28−), capable of
mediating only partial eﬀector functions and proliferative
capacity. Normally, CD8+ Tc e l ld i ﬀerentiation correlates
with a progressive loss in expression of the CCR7, CD28,
and CD27 markers and increased cytolytic capacity [33].
Hence, our results suggest that although CD8+ Tc e l l si n
RCC patients are capable of reacting against tumor cells,
their eﬀector functions and longevity are suboptimal due
to the absence of TCM cells and their incomplete state of
diﬀerentiation. These ﬁndings have important implications
f o rc a n c e ri m m u n o t h e r a p ya p p r o a c h e s[ 34], including DC-
based vaccines, and in this regard recently we have demon-
strated that dendritic cells (DCs) generated using IFN-α
and loaded with tumor antigens are capable of “revitalizing”
or expanding a therapeutically preferred cohort of anti-
tumor CD8+ Tc e l l s( T CM) from the PBMC of RCC patients
[35].
Other groups have investigated the proﬁles of human
CD8+ TCM,T EM,T EMRA using gene expression microarrays,
showing that TCM are characterized by a higher level
of basal and cytokine-induced STAT5/6 phosphorylation,
reﬂecting their superior capacity for self-renewal vs. eﬀector
memory cells, and in particular, TEMRA [11]. Interestingly,
we observed a down regulation of both STAT5/6 molecules
in patient CD8+ T cells, in association with their inferior
proliferative capacity, which is consistent with their known
dysfunction in vivo. These data suggest a role for STAT
pathway in the post activation survival of T cells and provide
new insights into the nature of a late (cell cycle) proliferation
block in the T cell compartment as a result of STAT6 deﬁ-
ciency. Indeed, in CD8+ T cells analyzed from RCC patients,
we observed a down regulation in JAK3/STAT5/6 expression
and corollary defects in cell cycle (G1/S) progression and
cell proliferation. These results establish the crucial role of
the JAK3/STAT5/6 signaling pathway in normal CD8+ Tc e l l
proliferation/diﬀerentiation, consistent with a recent report
by Jin et al. [36].
T cell activation and proliferation require several appro-
priate signals to complete transitions through the cell cycle,
from the G1 to the S phase. Interestingly, activated CD8+ T
cells from RCC patients, which exhibit reduced proliferative
responses against their own tumors, express increased levels
of p27KIP1, which is known to lead to G0 phase cell cycle
arrest and a slowed/arrested progression to G1/S transition.
These results are consistent with those reported by Zhang et
al. [28] where p27KIP1 was found to inhibit antigen-driven
TEM expansion in vivo. Our report adds to a very limited
literature in identifying a G1/S cell cycle regulatory defect in
T cells isolated from cancer patients, and it provides a better
understanding of mechanism(s) underlying tumor-induced
immune deviation that occurs during cancer progression.
One of the key events during the G1 phase is activation
of the transcription factor E2F4 [37]. E2F4 is a crucial
switch in the control of homeostasis and tumorigenesis
[21] and, together with Id2, serves as a critical regulator of
cell cycle progression. Speciﬁcally, Id2 has been suggested
to antagonize the regulation of the cell cycle by tumor
suppressor proteins [38]. Our analyses revealed a dramatic
reduction in E2F4 and Id2 expression in CD8+Tc e l l sf r o m
RCC patients vs. healthy donors after MLTC. These data
provide evidence for the importance of Id2 in enforcing
“normal” cell cycle progression in tumor-reactive T cells
harvested from RCC patients.
In conclusion, we have shown for the ﬁrst time that RCC
patients exhibit a functionally suboptimal anti-tumor CD8+
T cell repertoire based on defects in (the JAK3/STAT5/6)
intracellular signaling pathway that leads to T cell arrest in
the G0/G1 phase of the cell cycle and prevention of their
terminal diﬀerentiation. Furthermore, our data support the
conclusion that CD8+ T cell overexpression of p27KIP1
and/or loss of Id2 expression are characteristics of dys-
functional T cells in RCC patients, making these potential
therapeutic targets in the setting of patients with RCC.12 Journal of Biomedicine and Biotechnology
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